TOMI Receives Order For iHP Custom Engineered System From Major Pharmaceutical Company in Europe

FREDERICK, Md., Aug. 10, 2021 (GLOBE NEWSWIRE) — TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination, utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist products, has secured a project to install an iHP Custom Engineered System (CES) for a major pharmaceutical company in Europe.

Annually, TOMI submits multiple proposals to global pharmaceutical companies for custom installations of TOMI’s solutions for their manufacturing facilities. As COVID restrictions subside, proposals and projects that were put on hold due to the pandemic have started to resume.

The system will be used for sterilization of the filling room and adjacent personnel airlocks, including Restricted Access Barrier Systems (RABS) of both the filling machines and power feeding systems, all of which must meet the European cGMP requirements. With a projected completion date in the fourth quarter of 2021, the installation is anticipated to be TOMI’s most intelligent system to date, due to the advanced software programming required for operation.

“We were pleased to work with one of TOMI’s original international partners to secure this opportunity. The successful completion of this project will represent a significant opportunity to further develop our relationship with this major pharmaceutical company which has multiple Life Science campuses worldwide,” commented Elissa J. (E.J.) Shane, Chief Operating Officer of TOMI.

TOMI™ Environmental Solutions, Inc.: Innovating for a safer world^® 

TOMI™ Environmental Solutions, Inc. (NASDAQ:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology^® (BIT^™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT^™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP^™). Represented by the SteraMist^® brand of products, iHP^™ produces a germ-killing aerosol that works like a visual non-caustic gas.

TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences.

TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association.

For additional information, please visit http://www.tomimist.com/ or contact us at info@tomimist.com.

Forward-Looking Statements

This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to our partnership with a major pharmaceutical company in Europe and installation of our solutions at its facilities, potential further development with the partner and potential opportunities for TOMI in the future. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, the impact of COVID-19 pandemic on our business and customers; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.

INVESTOR RELATIONS CONTACT

John Nesbett/Jennifer Belodeau
IMS Investor Relations
jnesbett@imsinvestorrelations.com